Vaccine against Dengue Fever

The deadliest form of the mosquito-borne disease (Dengue) kills 22,000 people per year, according to the World Health Organisation. Dengue fever affects more than 400 million people a year across the world  in tropical and sub-tropical climates. It is a leading cause of hospital admissions in most Latin American and Asian countries, says the WHO.

Most of the victims are children. It is transmitted from person to person by the Aedes aegypti mosquito, which also spreads chikungunya, zika fever and other diseases.

French pharmaceutical company Sanofi had developed the vaccine, Dengvaxia, Some 40,000 people will receive the treatment in Mexico in an initial phase which makes Mexico move ahead of France, to tackle the spread of this virus.

The vaccine  is designed to prevent four types of dengue virus, said Sanofi. The company said it spent more than $1.6bn (£1bn) developing and creating the treatment. The first cases of dengue were registered in the 1950s in Thailand and the Philippines.

BBC Credit Link